A2M, which is involved in the Fas apoptotic signaling pathway, was upregulated in 18 cancers in the high-invasiveness score group and negatively correlated with sensitivity to eight drugs, such as Axitinib (r = − 0.503) and Dabrafenib (r = − 0.494). This evidence concerns the gene FAS and cancer.